DAWN VOLLMANN: Open Payments
NPI 1104335934 · BREA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$542 in 20 payments from 8 companies in 2025. Trend: 2023 $3,164 · 2024 $539 · 2025 $542
Food & beverage: $542
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 7 | $276 |
| Collegium Pharmaceutical, Inc. | 5 | $104 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $68 |
| Medtronic, Inc. | 1 | $22 |
| Curonix LLC | 1 | $20 |
| Abbott Laboratories | 1 | $20 |
| Globus Medical, Inc. | 1 | $20 |
| SPR Therapeutics, Inc | 1 | $13 |
Products named: QULIPTA, Belbuca, RELISTOR, UBRELVY, BOTOX, KYPHON EXPRESS II KYPHOPAK TRAY, PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A, ETERNA.
Industry payments across CA — which companies pay providers there.
